/R E P E A T -- Media Invitation - A Mobile Hospital to Increase Treatment Capacity for COVID-19 Patients/
POINTE-CLAIRE, QC, April 24, 2020 /CNW Telbec/ - The Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l'Ouest-de-l'Île-de-Montréal would like to invite media representatives to visit the mobile hospital before it opens its doors to COVID-19 patients. Once open, the mobile hospital will increase treatment capacity and optimize care services for patients on our territory.
Ms. Lynne McVey, President and CEO of the CIUSSS de l'Ouest-de-l'Île-de-Montréal, Ms. Manon Barbe, LaSalle borough mayor, and Mr. Pascal Mathieu, Canadian Red Cross Vice-President for Québec, will be on hand.
The visit will be carried out while respecting social distancing and instructions from the MSSS and Public Health concerning hygiene and security.
Note: Ms. Lynne McVey, President and CEO of the CIUSSS de l'Ouest-de-l'Île-de-Montréal, Ms. Manon Barbe, LaSalle borough mayor, and Mr. Patrick Mathieu, Canadian Red Cross Vice-President for Québec, will be available for one-on-one interviews with the media.
SOURCE Centre intégré universitaire de santé et de services sociaux de l'Ouest-de-l'Île-de-Montréal
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...